- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02253602
Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer (IMPROVE)
Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer: an Optimization and Pilot Study
The current standard treatment of resectable esophageal cancer consists of neoadjuvant chemoradiation followed by resection. However, some patients develop recurrent disease despite chemoradiation and additional (systemic) treatment might have been indicated. Other patients show a (nearly) complete response after chemoradiation and could possibly have been treated with a less extensive treatment regimen. In patients without a threatened circumferential resection margin (CRM) and lymph node metastases chemoradiotherapy could possibly be omitted.
Better stratification of patients with esophageal cancer is therefore urgently needed. Functional magnetic resonance imaging techniques (MRI) can provide in vivo, quantitative information on tumor biology and may prove to be a useful non-invasive tool for this purpose. In this project, ultra-small superparamagnetic particles of iron oxide (USPIO) enhanced MRI using ferumoxytol (Rienso®), diffusion weighted MRI (DWI) and T2* MRI will be developed, both in terms of improvement of acquisition and data processing techniques.
Studieöversikt
Detaljerad beskrivning
The outcome of esophageal cancer is poor, with an overall 5-year survival rate of 10% worldwide. In resectable esophageal cancer, outcome can be improved by multimodality treatment. The current standard treatment of resectable esophageal cancer consists of neoadjuvant chemoradiation followed by resection. In the Netherlands, the preferred chemoradiation regimen consists of carboplatin plus paclitaxel with concurrent radiotherapy in 23 fractions of 1.8 Gray.1 In a meta-analysis the benefit of chemoradiation over surgery alone for both adenocarcinoma and squamous cell carcinoma has been shown.2 However, not all patients benefit from this preoperative treatment regimen. Some patients develop recurrent disease despite chemoradiation and additional (systemic) treatment might have been indicated. In contrast, in other patients a (nearly) complete response is observed after chemoradiation and those patients could possibly have been treated with a less extensive treatment regimen. Furthermore, in patients without a threatened circumferential resection margin (CRM) and lymph node metastases chemoradiotherapy could possibly be omitted, reducing patients' risk for complications and unnecessary, expensive treatment. Thus, stratification of patients with esophageal cancer is urgently needed. Functional magnetic resonance imaging techniques (MRI) can provide in vivo, quantitative information on tumor biology and may prove to be a useful non-invasive tool for this purpose. In this project, ultra-small superparamagnetic particles of iron oxide (USPIO) enhanced MRI using ferumoxytol (Rienso®), diffusion weighted MRI (DWI) and T2* MRI will be developed, both in terms of improvement of acquisition and data processing techniques. For patients with esophageal cancer, the proposed acquisition techniques and data processing have not been performed before.
Objectives of the study
- To determine the optimal acquisition technique for USPIO enhanced MRI and DWI and T2* MRI of esophageal cancer in terms of signal-to-noise ratio, time resolution and spatial resolution.
- To determine the optimal data processing approach for USPIO enhanced MRI, DWI and T2* MRI of esophageal cancer.
- To explore the correlation between lymph node involvement on USPIO enhanced MRI in relation to results obtained at pathological examination.
- To explore the correlation of DWI and T2* MRI of esophageal cancer in relation to stromal involvement and markers of hypoxia and vasculature obtained at pathological examination.
- To explore the accuracy of MRI concerning circumferential tumor delineation compared to pathological examination.
- To determine the feasibility to detect lymph node involvement on USPIO enhanced MRI in initial staging, prior to preoperative chemoradiation therapy.
- To determine the correlation between lymph node involvement on pre-treatment USPIO MRI in relation to results obtained at pathology after complete treatment.
The project will be executed in four steps:
- Optimization of acquisition and data processing techniques of USPIO MRI, DWI and T2* in five healthy volunteers to optimize field of view, number of slices, slice thickness (objectives 1 and 2).
- Assessment of ferumoxytol dose-response with three different dose levels at three different time points in six healthy volunteers (two per dose-level) (objectives 1 and 2).
- Using the data of (1) and (2): assessment of USPIO MRI, DWI and T2* MRI in 20 esophageal cancer patients with clinically suspect lymph nodes directly before surgery (objectives 3, 4 and 5).
- Using the data of (1) and (2): assessment of USPIO MRI, DWI and T2* MRI in 10 esophageal cancer patients with clinically suspect lymph nodes, before initial start of the treatment (objectives 6 and 7).
For step 1 and 2 we aim to include healthy volunteers; for step 3 and 4 we aim to include patients with esophageal cancer.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Noord Holland
-
Amsterdam, Noord Holland, Nederländerna, 1105AZ
- Academic Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients with biopsy proven esophageal cancer (squamous cell carcinoma or adenocarcinoma)
- Suspected nodal involvement on EUS or CT at diagnosis.
- WHO-performance score 0-2
- Scheduled for surgery
- Written informed consent
Exclusion Criteria:
- Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol
- Contra-indications for MR scanning, including patients with a pacemaker, cochlear implant or neurostimulator; patients with non-MR compatible metallic implants in their eye, spine, thorax or abdomen; or a non-MR compatible aneurysm clip in their brain; patients with severe claustrophobia
- Active inflammatory diseases
- History of anaphylaxis or other hypersensitivity reactions
- History of iron overload
- History of abnormal liver function, or elevated liver enzymes (ALAT, ASAT > 3 times upper limit of normal)
- Elevated Serum Transferrin Saturation (TSAT) (>50%) or hemoglobin (>10.5mmol/L)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Ferumoxytol Dose optimization
We will assess three different dose levels of Ferumoxytol (4 mg/kg, 6 mg/kg, 8 mg/kg). Images will be acquired at baseline (before Ferumoxytol administration), during injection of Ferumoxytol and 24, 48 and 72 hours after Ferumoxytol administration to identify the optimal moment of scanning.To assess whether USPIOs are sufficiently cleared within 12 weeks from lymph nodes, the MRI scans will be repeated in all six volunteers at 12 weeks after Ferumoxytol administration. Thus, volunteers will undergo an MRI scan for five times. Ferumoxytol is administered only once |
maximum rate of administration 1 ml/sec
Andra namn:
|
Experimentell: Before Surgery
Twenty patients will be measured directly before surgery.
Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, depending on the results of the dose optimization study.
MR parameters will be correlated with pathology data.
|
maximum rate of administration 1 ml/sec
Andra namn:
|
Experimentell: Before Neoadjucant therapy
Ten patients will be measured before start of neoadjuvant chemoradiation.
Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, based on the dose optimization study.
MR parameters will be correlated with pathology data.
|
maximum rate of administration 1 ml/sec
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
USPIO MRI
Tidsram: 24, 48 or 72 hours after USPIO administration
|
For USPIO enhanced MRI the main endpoint is the change in T2 and T2* at the tumor and lymph nodes on MRI after the administration of USPIO.
|
24, 48 or 72 hours after USPIO administration
|
DWI/IVIM MRI
Tidsram: 1 hour before USPIO administration
|
For DWI the main endpoint is the perfusion fraction f and the diffusion coefficient D obtained by IVIM of the primary tumor.
|
1 hour before USPIO administration
|
T2* MRI
Tidsram: 1 hour before USPIO administration
|
For T2* MRI the main endpoint is T2* of the primary tumor
|
1 hour before USPIO administration
|
Ferumoxytol dose response
Tidsram: 24, 48, 72 hours and 12 weeks after the administration of Ferumoxytol
|
For Ferumoxytol dose evaluation the main endpoint is the change in T2 and T2* at the tumor and lymph nodes on MRI at 24, 48, 72 hours and 12 weeks after the administration of Ferumoxytol.
|
24, 48, 72 hours and 12 weeks after the administration of Ferumoxytol
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer
- Neoplasmer efter plats
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Gastrointestinala sjukdomar
- Neoplasmer i huvud och hals
- Esofagussjukdomar
- Esofagusneoplasmer
- Hematinik
- Farmaceutiska lösningar
- Parenterala näringslösningar
- Ferrosoferrioxid
Andra studie-ID-nummer
- NL48757.018.14
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Esofagusneoplasmer
-
University Hospital, LilleFederation of Research in Surgery (FRENCH); French Eso-Gastric Tumors Working... och andra samarbetspartnersAvslutadEsophageal neoplasm | Esophageal sjukdomFrankrike
-
Cancer Institute and Hospital, Chinese Academy...Peking University Cancer Hospital & Institute; Tianjin Medical University... och andra samarbetspartnersRekryteringEsophageal Neoplasm Metastatisk | Esophageal cancer stadium IVbKina
-
Baylor College of MedicineCreo Medical LimitedHar inte rekryterat ännuEsophageal neoplasm | Endoskopisk submukosal dissektion | Esophageal polyp | Bipolär elektrokauteriFörenta staterna
-
Baylor College of MedicineIndragenEsophageal neoplasm | Endoskopisk submukosal dissektion | Esophageal polyp | Bipolär elektroköteriFörenta staterna
-
US Endoscopy Group Inc.AvslutadBarrett Esophagus | Esophageal neoplasm | Esofagusstenos | Esophageal dysplasi | Bronkial neoplasm | Stenos av bronk eller luftstrupeFörenta staterna
-
Region SkaneAvslutad
-
Roswell Park Cancer InstituteIndragen
-
University Hospital, LilleRekryteringEsophageal neoplasmFrankrike
-
Dr Kundan Singh ChufalAktiv, inte rekryterandeEsophageal neoplasmAustralien, Indien
-
Edelman, Martin, M.D.Bristol-Myers SquibbOkändEsophageal neoplasmFörenta staterna
Kliniska prövningar på Ferumoxytol
-
Michael IvNational Cancer Institute (NCI)IndragenChildhood Brain NeoplasmFörenta staterna
-
Massachusetts General HospitalAvslutadPapillärt karcinom i sköldkörteln | Metastaserande medullär sköldkörtelcancer | Follikulär sköldkörtelcancer LymfkörtelmetastasFörenta staterna
-
Allegheny Singer Research Institute (also known...Aktiv, inte rekryterandeNeoplasmer i levern | Hepatocellulärt karcinom | Levermetastaser | Lever cancer | Leverkarcinom | Hepatocellulär cancer | Levercirros | Leverkarcinom | LeveratrofiFörenta staterna
-
OHSU Knight Cancer InstituteOregon Health and Science University; Radiological Society of North AmericaAvslutadSteg III rektalcancer AJCC v7 | Steg IIIA rektalcancer AJCC v7 | Steg IIIB rektalcancer AJCC v7 | Steg IIIC rektalcancer AJCC v7 | Lokalt avancerad rektalcancerFörenta staterna
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science University; National... och andra samarbetspartnersRekryteringAdenokarcinom i bukspottkörteln | Familjär bukspottkörtelcancer | Pankreatisk intraduktal papillär-mucinös neoplasmaFörenta staterna
-
Michael IvAvslutadHjärnskada | Hjärncancer | Hjärntumörer | Primär hjärnneoplasma | Ischemisk cerebrovaskulär olycka | Degenerativ störning i centrala nervsystemet | Infektionssjukdom i centrala nervsystemet | Centrala nervsystemet Vaskulär missbildning | Hemorragisk cerebrovaskulär olyckaFörenta staterna
-
The First Affiliated Hospital with Nanjing Medical...Rekrytering
-
Jason GagliaHarvard Medical School (HMS and HSDM); National Institute of Allergy and...Okänd
-
Dana-Farber Cancer InstituteIndragen
-
AMAG Pharmaceuticals, Inc.OkändPerifer arteriell sjukdom (PAD)Förenta staterna